Abstract

Purpose The aim of this study is to assess the typical doses associated with PET/CT examination in a large population and to evaluate the difference of effective dose estimation in fixed vs patient-adapted activity utilizing the same imaging protocols. Doses differences in the urinary bladder are also estimated for PET examination. Methods and materials DoseWatch™ tracking system was utilized to collect patient information and to measure effective dose (for WB 18 F-FDG PET/CT) and organ dose data (for PET only) associated with a fixed activity by retrospectively analyzing existing data. For CT examination DLP values and effective dose data was collected; for PET examination DoseWatch™ provides the administered activity, the effective and the organ doses, based on ICRP 106. Effective and organ dose (for PET only) in a PET/CT examination where the administered activity is adapted to the patient’s weight will be estimated from the same database using a theoretical calculation. The dose in the urinary bladder is also assessed on theoretical calculations. Results Dose data from 6900 CT and 1700 WB 18F-FDG PET were collected. CT mean DLP (mGy*cm) data values were: 1481.3 (76.1–7700.9) and mean effective doses (mSv): 15.2 ± 4.9. Mean administered activities (MBq) and effective doses (mSv) for 18F-FDG PET are: 333.9–6.4. The mean total effective doses (mSv) due to both modality are: 21.5 ± 5.2. equivalent doses (mSv) to urinary bladder are: 43.7 ± 5.8. Conclusions The implementation of a dose tracking system in nuclear medicine is of great value for accurate and regular recording, reporting and analysis of patient’s effective doses.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call